Skip to content

Author

R. Chelluri

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer

This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.

Z. Su, Tyler S. Garman, Carlos A. Rivera López et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.